Yao-Chang Xu, Abbisko Therapeutics founder and CEO

Qim­ing-backed Ab­bisko makes $200M+ Hong Kong de­but, as a SPAC and Agenus spin­out al­so price on Nas­daq

Three new en­ti­ties priced their pub­lic de­buts late Thurs­day and ear­ly Fri­day, in­clud­ing a SPAC, a tra­di­tion­al Nas­daq IPO and a Chi­nese biotech join­ing the Hong Kong In­dex.

Shang­hai-based Ab­bisko Ther­a­peu­tics raised the most mon­ey of the tri­umvi­rate, gar­ner­ing $226 mil­lion in its Hong Kong de­but and pric­ing at HK$12.46, or rough­ly $1.60 in US dol­lars. The blank check com­pa­ny fol­lowed up with a $150 mil­lion raise, while MiNK Ther­a­peu­tics priced on Nas­daq at $12 per share and a $40 mil­lion raise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.